Movement Alert｜Moderna, Inc. Rises 5.31% in Regular Trading, First mRNA Flu Vaccine Wins FDA Approval

Market Focus08-07

On August 7, Moderna, Inc. rose 5.31% in regular trading, trading at $56.705/share, with turnover of $69.93 million. The rally was driven by the company's announcement that its seasonal influenza vaccine mFLUSIVA officially received U.S. FDA approval.

The approval covers use in adults aged 50 and above, marking the first mRNA-based vaccine to enter the flu market and Moderna's fourth FDA-cleared product in the U.S. The company expects the vaccine to become available for the 2026-2027 respiratory virus season, with retail availability anticipated within weeks. The vaccine is also under regulatory review in Australia, Canada, and Europe, suggesting further upside from global commercialization.

The approval came after a period of rare public disagreement between Moderna and FDA regulators, making the clearance a significant milestone. Multiple institutions had recently raised price targets ahead of the PDUFA date, including UBS to $50 and Goldman Sachs to $67, while the company's Q2 EPS of -$1.97 also beat consensus estimates.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

1

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1163878004?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 22:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163878004","market":"us","top_or_hot":-1,"title":"Movement Alert｜Moderna, Inc. Rises 5.31% in Regular Trading, First mRNA Flu Vaccine Wins FDA Approval","media":"Market Focus","content":"<p><p>On August 7, Moderna, Inc. rose 5.31% in regular trading, trading at $56.705/share, with turnover of $69.93 million. The rally was driven by the company's announcement that its seasonal influenza vaccine mFLUSIVA officially received U.S. FDA approval.</p><p>The approval covers use in adults aged 50 and above, marking the first mRNA-based vaccine to enter the flu market and Moderna's fourth FDA-cleared product in the U.S. The company expects the vaccine to become available for the 2026-2027 respiratory virus season, with retail availability anticipated within weeks. The vaccine is also under regulatory review in Australia, Canada, and Europe, suggesting further upside from global commercialization.</p><p>The approval came after a period of rare public disagreement between Moderna and FDA regulators, making the clearance a significant milestone. Multiple institutions had recently raised price targets ahead of the PDUFA date, including UBS to $50 and Goldman Sachs to $67, while the company's Q2 EPS of -$1.97 also beat consensus estimates.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Moderna, Inc. Rises 5.31% in Regular Trading, First mRNA Flu Vaccine Wins FDA Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Moderna, Inc. Rises 5.31% in Regular Trading, First mRNA Flu Vaccine Wins FDA Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 22:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, Moderna, Inc. rose 5.31% in regular trading, trading at $56.705/share, with turnover of $69.93 million. The rally was driven by the company's announcement that its seasonal influenza vaccine mFLUSIVA officially received U.S. FDA approval.</p><p>The approval covers use in adults aged 50 and above, marking the first mRNA-based vaccine to enter the flu market and Moderna's fourth FDA-cleared product in the U.S. The company expects the vaccine to become available for the 2026-2027 respiratory virus season, with retail availability anticipated within weeks. The vaccine is also under regulatory review in Australia, Canada, and Europe, suggesting further upside from global commercialization.</p><p>The approval came after a period of rare public disagreement between Moderna and FDA regulators, making the clearance a significant milestone. Multiple institutions had recently raised price targets ahead of the PDUFA date, including UBS to $50 and Goldman Sachs to $67, while the company's Q2 EPS of -$1.97 also beat consensus estimates.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1163878004","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163878004","pubTimestamp":1786113555,"columns":[{"name":"Product Release","id":31,"label_key":"productRelease"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, Moderna, Inc. rose 5.31% in regular trading, trading at $56.705/share, with turnover of $69.93 million. The rally was driven by the company's announcement that its seasonal influenza...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"动态警报|Moderna, Inc. 常规交易上涨 5.31%，首款 mRNA 流感疫苗获得 FDA 批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"On August 7, Moderna, Inc. rose 5.31% in regular trading, trading at $56.705/share, with turnover of $69.93 million. The rally was driven by the company's announcement that its seasonal influenza vaccine mFLUSIVA officially received U.S. FDA approval.The approval covers use in adults aged 50 and above, marking the first mRNA-based vaccine to enter the flu market and Moderna's fourth FDA-cleared product in the U.S. The company expects the vaccine to become available for the 2026-2027 respiratory virus season, with retail availability anticipated within weeks. The vaccine is also under regulatory review in Australia, Canada, and Europe, suggesting further upside from global commercialization.The approval came after a period of rare public disagreement between Moderna and FDA regulators, making the clearance a significant milestone. Multiple institutions had recently raised price targets ahead of the PDUFA date, including UBS to $50 and Goldman Sachs to $67, while the company's Q2 EPS of -$1.97 also beat consensus estimates.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1163878004","isCrawlerRequest":true}